Abstract
Prostasin protein has been found to be a useful marker for determination of the invasiveness of and as a means to treat human carcinomas. Using RT-PCR and western blot analyses, prostasin protein and mRNA expression were found in normal human prostate epithelial cells and the human prostate cancer cell line LNCaP, but not in the highly invasive human prostate cancer cell lines DU-145 and PC-3. Imunohistochemistry studies of human prostate cancer specimens revealed a down-regulation of prostasin in high-grade tumors. Using RT-PCR and western blot analyses, prostasin protein and mRNA expression were found in a non-invasive human breast cancer cell line, MCF-7, while invasive human breast cancer cell lines MDA-MB-231 and MDA-MB-435s were found not to express either the prostasin protein or the mRNA. A non-invasive human breast cancer cell line, MDA-MB-453, was shown to express prostasin mRNA but not prostasin protein. Transfection of DU-145 and PC-3 cells with a full-length human prostasi
Document Type
Patent
Patent Number
US 6,864,093
Application Serial Number
10/235,255
Issue Date
3-8-2005
Current Assignee
UCFRF
Assignee at Issuance
UCFRF
College
Burnett School of Biomedical Sciences
Department
Molecular Biology & Microbiology
Allowance Date
8-10-2004
Filing Date
9-5-2002
Assignee at Filing
UCFRF
Filing Type
Nonprovisional Application Record
Donated
no
Recommended Citation
Chai, Xinqing; Chao, Julie; Chao, Lee; and Chen, Limei, "Method of identifying and treating invasive carcinomas (CIP)" (2005). UCF Patents. 355.
https://stars.library.ucf.edu/patents/355